SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Innovation as a value in healthcare priority-setting: the UK experience
16 references·0 citing·44 second hop
Innovation as a value in healthcare priority-setting: the UK experience (2019)Innovation as a value in healthcare prior…Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries (2017)Using health technology asses…Prioritarianism for Global Health Investments: Identifying the Worst Off (2015)Prioritarianism for Global He…Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold (2015)Methods for the estimation of…De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making (2015)De innovatione: The concept o…The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions (2014)The Influence of Cost‐Effecti…Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis (2014)Guidance on priority setting …HEALTH TECHNOLOGY ASSESSMENT, VALUE-BASED DECISION MAKING, AND INNOVATION (2013)HEALTH TECHNOLOGY ASSESSMENT,…Defining “Innovativeness” in Drug Development: A Systematic Review (2013)Defining “Innovativeness” in …SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE‐BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS‐SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN (2012)SOCIETAL VIEWS ON NICE, CANCE…Pharmacoeconomics: NICE's approach to decision‐making (2009)Pharmacoeconomics: NICE's app…The NICE Cost-Effectiveness Threshold (2008)The NICE Cost-Effectiveness T…Priority setting in health care: Lessons from the experiences of eight countries (2008)Priority setting in health ca…NICE Guide to the Methods of Technology Appraisal (2008)NICE Guide to the Methods of …Coverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’ (2006)Coverage Options For Promisin…National Institute for Clinical Excellence and its value judgments (2004)National Institute for Clinic…Separate spheres and indirect benefits (2003)Separate spheres and indirect…The PHQ-9 (2001)Methods for the Economic Evaluation of Health Care Programmes (2005)A Brief Measure for Assessing Generalized Anxiety Disorder (2006)Cost–effectiveness thresholds: pros and cons (2016)The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought (2016)Hedonic Prices and Implicit Markets: Product Differentiation in Pure Competition (1974)CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS? (2014)Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness (2015)Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L (2018)Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients (2001)QALY maximisation and people's preferences: a methodological review of the literature (2004)Response Rates and Nonresponse Errors in Surveys (2012)Attributes and weights in health care priority setting: A systematic review of what counts and to what extent (2015)The Politics of Evidence (Open Access) (2016)Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature (2017)Use of Indirect and Mixed Treatment Comparisons for Technology Assessment (2008)Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? (2009)Smoking and health-related quality of life in English general population: implications for economic evaluations (2012)Mapping to Estimate Health-State Utility from Non–Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report (2017)A Theory of Justice (1971)Cost-Effectiveness in Health and Medicine (1996)Deliberations about deliberative methods: issues in the design and evaluation of public participation processes (2003)Priority setting in health: origins, description and application of the Australian Assessing Cost–Effectiveness initiative (2008)The Economic Analysis of Prevention in Mental Health Programs (2011)‘You’re on the waiting list’: An interpretive phenomenological analysis of young adults’ experiences of waiting lists within mental health services in the UK (2022)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)EuroQol: the current state of play (1996)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)Systematic reviews in the social sciences: a practical guide (2006)Delivering affordable cancer care in high-income countries (2011)Defining equity in health (2003)Closing the gap in a generation: health equity through action on the social determinants of health (2008)Ethical priority setting for universal health coverage: challenges in deciding upon fair distribution of health services (2016)Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness (2016)Universal health coverage, priority setting, and the human right to health (2017)A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework (2017)Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward (2019)Coverage with Evidence Development: An examination of conceptual and policy issues (2007)How Can We Support the Use of Systematic Reviews in Policymaking? (2009)Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers (2010)A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States (2020)The cost-effectiveness of digital health interventions: A systematic review of the literature (2022)
this work references cited by second hop

References

  • 2008The NICE Cost-Effectiveness Threshold868 cited
  • 2015Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold857 cited
  • 2004National Institute for Clinical Excellence and its value judgments767 cited
  • 2008Priority setting in health care: Lessons from the experiences of eight countries312 cited
  • 2017Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries306 cited
  • 2014The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions232 cited
  • 2008NICE Guide to the Methods of Technology Appraisal226 cited
  • 2006Coverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’210 cited
  • 2012SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE‐BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS‐SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN208 cited
  • 2014Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis183 cited
  • 2009Pharmacoeconomics: NICE's approach to decision‐making152 cited
  • 2013HEALTH TECHNOLOGY ASSESSMENT, VALUE-BASED DECISION MAKING, AND INNOVATION95 cited
  • 2015De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making72 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2003Separate spheres and indirect benefits61 cited
  • 2013Defining “Innovativeness” in Drug Development: A Systematic Review59 cited
  • 2015Prioritarianism for Global Health Investments: Identifying the Worst Off58 cited
  • Cited by

    No citing works inside the corpus for this window.